Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes

about

GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.Subcutaneous nodules secondary to exenatide once weekly: clinical and histological findings.

P2860

Q38602769-C25483E9-2E9B-4CF6-A29A-E99BBE9C591A Q46823969-C59C7F32-0291-4F2D-86D9-1BAAD2CE3E7C Q48276073-88C08B3A-6F07-4603-A2B4-7A143817F9AF

P2860

Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes

Item

http://www.wikidata.org/entity/Q38188871

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pathophysiological and pharmac ...... patients with type 2 diabetes

@en

type

Item

label

Pathophysiological and pharmac ...... patients with type 2 diabetes

@en

prefLabel

Pathophysiological and pharmac ...... patients with type 2 diabetes

@en

P1476

Pathophysiological and pharmac ...... patients with type 2 diabetes

@en

P2093

Samuel S Grossman

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Review paper: absorbable polymeric surgical sutures: chemistry, production, properties, biodegradability, and performance

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Standards of medical care in diabetes--2014

P2888

s12325-014-0101-4

P304

247-263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S12325-014-0101-4

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260242219

http://www.w3.org/2001/XMLSchema#string

P6179

1042698145

http://www.w3.org/2001/XMLSchema#string

P698

24535624

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

peptide

type-2 diabetes

maturity-onset diabetes of the young

fluids and secretions

P932

3961598

http://www.w3.org/2001/XMLSchema#string

Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes

about

P2860

P2860

Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P921

P932